pharmaceutical challenges Archives - Business Intelligence

Tag: pharmaceutical challenges

Pharma secondary packaging market

Infiniti’s Competitive Intelligence Solution for A Prominent Company in The Pharma Secondary Packaging Market: Exploring Key Packaging Innovations And competitive landscape Insights

In pharmaceuticals, secondary packaging constitutes the packaging which does not come in direct contact with the dosage form. Pharma secondary packaging is becoming widely adopted and essential as they offer critical functionalities, such as, for physical and barrier protection, secondary containment, adherence to regulations, and consumer safety. It also creates a buffer and protects primary packages from each other during transportation.

Business challenge

A prominent pharmaceutical company headquartered in San Francisco, CA sought to explore the changing trends in the secondary pharma packaging market by focusing the research on major design/technology innovations and best practices adopted by leading players in the pharma secondary packaging market. Through the engagement, the client wanted to support their future packaging developments and track industry trends over time. By leveraging Infiniti’s competitive intelligence solution, the pharmaceutical company wanted to understand the competitor landscape in the US and European pharma secondary packaging market, new features of secondary packaging being incorporated by competitors, product portfolio descriptions, and competitor strategies to promote adherence.   

Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma secondary packaging market? Request a complimentary proposal.

Our Approach

Experts at Infiniti Research started by delving deeply into the pharma secondary packaging market transformation over the past decade in the US and Europe. This involved a well-balanced combination of primary and secondary research. Telephonic discussions were undertaken with over 45 respondents with expertise in the development, sales, marketing, and usage of products and services related to secondary packaging market such as pharmaceutical packaging specialists, packaging engineers, and packaging development experts. The secondary research undertaken by our analysts included comprehensive research materials from company websites, industry news CPA, HCPC, CHPA, packaging digest, and public database.

Through extensive competitive intelligence study and research methodologies, experts at Infiniti Research were able to identify the top pharma secondary packaging designs that are predominantly used. This includes medication adherence packaging, extended labels, and increasing use of sustainable materials in pharma secondary packaging. Furthermore, Infiniti’s competitor landscape assessment also identified some of the key competitors in the US and Europe, their respective packaging initiatives, and critical initiative undertaken to promote adherence.

With a focus to ensure product integrity, better manufacturing efficiency, and enhancing customer satisfaction, experts at Infiniti Research have identified that companies are developing innovative technologies such as thermochromic indicators and contemporary cartons designs. Furthermore, with Infiniti’s recommendation, the client adopted robotics and process automation that significantly improves production output, lowers operating cost, and enhances worker safety.

Business Impact

By leveraging Infiniti’s competitive intelligence solution, the client was able to successfully track their key market competitors and identify some of the most innovative and viable trends in the pharma secondary packaging market. Apart from this client was also able to:

  • Increase investments on their primary and secondary packaging lines by adopting technologies which result in faster turn-around time, fewer errors, and higher adaptability to incorporate and reproduce design changes
  • Collaborate with the CPO to formulate innovative packaging designs which are senior-friendly, child- resistant, medication adherence promoting, and offers unique dispensing mechanisms
  • Expedite early market entry for biologics and personalized medicine by identifying advancements such as 3D printing in pharmaceutical packaging
  • Reduce operational cost by 30% within this first quarter by adopting RPA into packaging operations
  • Focus on packaging designs that are cost-effective and have shorter production turnaround times
  • Incorporate adherence features in the secondary packaging design to help practitioners promote the use of the drugs to the patients
  • Build an effective planning and production process to minimize packaging errors and prevent product recalls, saving the company over $1.2 million within six months

For similar engagements for your business, get in touch with an industry expert

pharmaceutical industry

Illuminating the impact of Brexit on Europe’s Pharmaceutical industry

Pharmaceutical industry products are in the list of top five products that are most imported and exported from the UK to the EU and vice versa.

Brexit can have several implications of Europe’s pharmaceutical industry. From product development to market approval to the shipping of medicines and medical devices, pharmaceutical companies can expect to be affected in a broad range of areas. Companies in the pharmaceutical industry in the UK will have to manage the impact of Brexit carefully to prevent some of the negative aspects. However, uncertainty will have adverse effects on pharmaceutical and life sciences companies in other European countries as well. Experts at Infiniti predict how Brexit will affect life science and pharmaceutical industry.

Rising demand for personalized treatments, an ageing population, and the rise of new manufacturing technologies are some of the primary growth opportunities for the UK pharmaceutical sector. Request a free proposal to know how our solutions can help you stay prepared to cope with the market trends and changes.

Relocating European Medicines Agency (EMA)

One of the key pharmaceutical industry market access challenges that Brexit brings along with it, irrespective of the path it takes is related to the future location of the European medicines agency. Since its inception in 1995, EMA had been located in London. However, the Netherlands has now won the bid to host new EMA headquarters post-Brexit. With the EMA headquarters soon moving to Amsterdam, they may implement several changes to rules for medicinal products that are developed and tested in the UK. However, the extent of Brexit-induced changes to the pharmaceutical industry has yet to be decided.

Movement of people and pharma products

Pharma products form a considerable part of goods that are exported to and from the UK. Any post-Brexit hurdles to the free movement of goods could mean trouble for those supplies, potentially leading to temporary drug shortages. This is especially true in the case of drugs such as medicinal insulin that are not manufactured in the UK nor is it easily stored, as it requires temperature-controlled conditions. In order to reduce the risk of drug shortages in the case of a no-deal Brexit, the British government has asked pharmaceutical companies to add a minimum of six weeks’ worth of additional backup supply of medicines to their usual buffer stocks by the exit date, and to ensure that contingency plans were in place for drugs with shorter shelf lives. However, it is not only the movement of medicines that’s at risk. As the possibility of stricter rules regarding the flow of people between the UK and the EU looms, companies in the pharmaceutical industry are concerned about their ability to attract talent from outside Britain in the future. It is vital that pharmaceutical companies to still be able to access the best talent from around the world.

Emerging markets represent an exceptional opportunity for the pharmaceutical sector. Get in touch with our experts for more insights on how to capture the true value of the pharmaceutical market.

Change in the UK’s contribution to drug regulation

UK plays a major role in drug regulation in the EU through the work of the Medicines and Healthcare Products Regulatory Agency (MHRA). The UK frequently serves as rapporteur/co-rapporteur in the EU’s centralized procedure and as the reference member state in the decentralized procedure. It will prove to be a challenging task to replace the MHRA’s capacity and expertise, particularly if the timetable for reform is aggressive.

 

Safe supply of blood and organs

Another pressing challenge faced by companies in the pharmaceutical industry due to Brexit is linked to ensuring blood and blood products are safe. If there is a no-deal Brexit, the EU Blood Directives will not apply to the UK and it will be considered a third country by the EU regarding sharing blood, blood components, and information. The UK Government has declared that in the event of a no-deal, the current blood safety and quality standards for blood and blood components will remain the same, and therefore adhere to EU standards, allowing them to be imported into the EU. Similarly, the UK Government has laid out its provisions for ensuring the supply, as well as the safety and quality, of organs, tissues, and cells in the event of a no-deal. The UK would no longer be part of the EU Organ and EU Tissues and Cells directives, however, relevant UK establishments, such as stem cell laboratories and fertility clinics, would be required to work to the same standards. These organizations would need to individually agree on import and export of the products with EU and EEA authorities and establishments.

Learn more about Infiniti’s solutions for the pharmaceutical industry.

Recent Posts

Pharmaceutical manufacturing

IoT in Pharmaceutical Manufacturing: How it will Make a Difference

Internet of things (IoT) has the power to revolutionize pharmaceutical manufacturing in everything ranging from drug discovery to remote patient access and monitoring. Top pharma companies around the globe are increasingly adopting IoT technologies in their manufacturing plants in an effort to achieve optimization and improve process efficiency. Earlier, different data formats for different processes in a pharmaceutical manufacturing plant made data access and interpretation a significant challenge for effective communication. IoT technologies enable standardization within a pharmaceutical manufacturing plant by effectively connecting network, equipment, and systems across the plant. Furthermore, Pharma companies can also use IoT technologies to gain access to real-time data and visibility of operations through the entire manufacturing process. Here’s a detailed look on how IoT will transform pharmaceutical manufacturing.

Despite technological advancements, the pressing matter pharma companies have to address is how to achieve more control over their operations within and outside the facilities to remain competitive, optimize time-to-market, avoid shipment delays, and reduce the waste. Request a free proposal to know we can help overcome this dilemma.

IoT in Pharmaceutical Manufacturing

Pharmaceutical manufacturingIndustrial mechanics and maintenance

Although the use of industrial monitoring devices are already widespread in the pharmaceutical industry, real-time status information is yet to be widely available. Using pharma IoT monitoring sensors companies can instantaneously feed all relevant facility data into a single dashboard, alerting a supervisor in case of any abnormal conditions or urgent maintenance requirements. IoT in pharmaceutical manufacturing will also enable handling critical conditions remotely.

Managing pharma supply chain

Once the drugs leave the manufacturing plant, they travel through different modes of transport and may be subject to varying temperatures and weather conditions. Although in most cases care is undertaken to maintain the packages within the prescribed temperatures, chances of variations during transit cannot be completely ruled out. IoT can be helpful in such situations to provide real-time data to manufacturers every step of the way with improved supply chain visibility. The temperature changes or any damage to the products will be immediately notified to the manufacturers and determine whether the drugs are fit to sell or not.

In the pharmaceutical industry, mistakes have serious consequences, so progress will always be slow and cautious. Get in touch with our experts to learn how our solutions can help companies in the pharmaceutical industry.

Controlling drug manufacturing environment

In pharmaceutical manufacturing, sub-optimal environmental conditions can often prove to be fatal. However, this obstacle can be easily handled with the help of IoT. Pharma IoT establishes transparency in drug production and storage environment by allowing multiple sensors to monitor environmental indicators such as temperature, humidity, radiation, and light in real-time.

Learn more about Infiniti’s solutions for the pharma industry

Competitor analysis

Top Manufacturing Trends Flourishing in the Pharma Industry

The global economic uncertainties, increasing healthcare costs and expiring patents are putting pharma companies in a state of turmoil. However, on the brighter side, the rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs, and innovations in manufacturing trends will sustainably modify the global pharmaceutical landscape. Moreover, the increasing prevalence of chronic diseases and the growing demand for medications, high market growth, new medicines, and therapy forms, changing regulations, and progressing digitization are going to give birth to new manufacturing trends to meet the growing demand.

Manufacturing trends in the pharma industry

Process analytical technology

This initiative sets a legal framework in the USA aiming to motivate pharma companies to improve the production process and achieve consistent quality while reducing waste and costs. In order to comply with this regulation and the changing manufacturing trends, pharma companies need to have systems in place that ensure detailed monitoring of their continuous and batch processes. Process analytical technology is one of the vital manufacturing trends that enables and drives continuous manufacturing. It was identified as one of the most important manufacturing trends in pharma companies along with integrated manufacturing business and automation processes.

banner IR

Digitization and labeling information

Effective tracking, tracing, and labeling is a mandatory proof of authenticity and prevention of drug counterfeiting. Digitization of labeling information has resulted in greater emphasis being placed on collecting, securing, and processing digital data about pharma products.

Low-volume drugs

There are several issues relating to introducing new drugs in the market. This includes manufacturing issues as well, so a review of manufacturing trends in approvals of new molecular entities (NMEs) can provide insight into manufacturing activity. A key trend in NME approvals is the increased share of orphan drugs approved as NMEs. Orphan drugs are defined as drugs that treat diseases which are known to affect 200,000 or fewer people, as defined by the US Food and Drug Administration (FDA). The FDA provides incentives, including market-exclusivity benefits, for developing orphan drugs. Due to a smaller patient population, these drugs are typically produced in lower volumes when compared to primary care drugs.Get More Info

Risk-based manufacturing inspections

The FDA is continuing its plan to use a risk-based selection model for manufacturing inspections in the pharma industry. This forms a part of its strategy to allocate resources more effectively and gain greater parity between inspections of domestic and foreign drug-manufacturing facilities. During September 2018), the FDA published an internal policy that outlines the agency’s risk-based, site-selection model for inspecting foreign drug-manufacturing facilities. The FDA prioritizes inspections of sites regardless of their location with the help of a risk-based site-selection model. This is one of the critical manufacturing trends that pharma companies must watch out for.


Gain more insights into how Infiniti’s solutions can help pharma companies

Contact US

Pharmaceutical Industry

Pharmaceutical Industry Challenges 2018 – Major Barriers to Growth Prospects

Though there are several speculations about the stagnant growth of the pharmaceutical industry, recent technological innovations are expected to facilitate growth in the years to come. Click To Tweet

The huge shift of the population to urban areas and increased accessibility of people to healthcare services has opened doors to a wider target market for the pharmaceutical industry players. These emerging markets are becoming increasingly important for pharma companies. However, to be successful in the market, it becomes essential for companies in the pharmaceutical industry to shift from a marketing and sales-focused model to an access-driven commercial model. Additionally, with the governments of several countries making healthcare a priority in their policies, the future looks bright for pharma companies. But on the flip side, the market conditions and several other factors might not entirely be in favor of pharma companies. There are several challenges lying ahead for pharmaceutical industry players, which they need to combat before heading on the road to success:

TOP PHARMACEUTICAL INDUSTRY CHALLENGES

Healthcare policy reformsContact US

The US is the top player in the global pharmaceutical market. However, the changing healthcare reforms are affecting the pharmaceutical industry players in a big way. The Patient Protection and Affordable Care Act (PPACA), which is also known as Obamacare, is expected to undergo some significant reforms under the new government. Though healthcare policy reforms are on the top of the priority list for the new presidential administration, we are yet to see how these policies are going to affect the pharmaceutical industry in the longer run.

Impact of new technologies on pharma

Players in the pharmaceutical industry are still unsure about how the new digital technologies are going to impact drug development and commercialization. Several industrial experts feel that emerging technologies such as AI and 3D printing will cause radical changes in the business models, operations, workforce, and cybersecurity. The adoption of these technologies would also have additional benefits such as the ability to establish a digital supply chain in reducing manufacturing costs.

cta ir

Increased focus on ‘patient-centric’ healthcare

One of the most popular trends in the healthcare industry in recent times is the shift towards a patient-centric care model. Bringing the spotlight to the quality of care given to patients and making them active participants in the treatment process has put immense pressure on the pharmaceutical industry players. Furthermore, increasing regulatory measures are forcing pharma companies to deliver the best quality of services to prevent any regulatory actions.Request Proposal

Slower growth rate in emerging markets

Companies in the pharmaceutical industry have been reaping significant benefits from the emerging markets, but the recent economic slowdown in these markets has had a negative impact on the profit potential. The reduction in the GDP of these low-income countries with high pharmaceutical growth prospects has triggered a corresponding reduction in the volume growth. Unless these emerging markets pick up on their economic growth, the development of pharma companies in these markets will prove to be difficult.

Venture capital

The flow of venture capital is an essential factor for the smooth functioning of companies in the pharmaceutical industry. But the bad news is that the investments in venture capital-backed companies in the US has shown a constant decline in the recent past with fluctuations in deals and dollar. A significant challenge lying here for players in the pharmaceutical industry is to win back the confidence of investors in the sector.

cta ir

Read an updated version of this article:

Pharmaceutical Industry Challenges to Watch Out for in 2019

 


To know more about the challenges in the pharmaceutical industryAsk an analyst


 

Pharmaceutical Industry

Pharmaceutical Industry Challenges – Roadblocks to the Industry’s Growth Prospects

The growth of the pharmaceutical industry has slowed down over the last few years. Experts suggest that the market has reached its saturation level. However, due to recent advances in technological innovation, the market is anticipated to witness further growth. Innovations such as wearable devices, real-world evidence, telemedicine, nanotechnology, and precision medicine are expected to change the landscape of the pharmaceutical industry. Despite such innovations, the pharma industry has started facing some tough tests recently.

Copy of Copy of banner IR (1)

Pharmaceutical Industry Challenges

Pharmaceutical Industry Growth Slowdown

Numerous market research reports have highlighted the fact that the pharmaceutical industry will experience a slowdown in the next few years since the major markets are nearing their saturation point. Historically, the pharma industry has experienced a sporadic increase in growth rates with the introduction of generic medicines for diseases like hepatitis and cancer. Therefore, it can be estimated that the growth prospects of the pharmaceutical industry are currently dependent on the invention of effective medications.

Biosimilar Showdown

Biosimilar drugs are capable of increasing the efficacy of medicines and patient safety at an economical cost. However, big players in the pharmaceutical industry are opposed to biosimilars as it’s hurting their innovative capacities. In the US, the FDA has approved 41 new medicines, the most in 18 years, with more drugs in the pipeline. The recent Sandoz vs. Agmen case has also brought into limelight the fact that the cheaper version of complex and pricier drugs, called biosimilars, get to patients faster.

With over 15 years of experience in serving customer across the globe, we can help you to gather detailed insights into the market. Contact us today!

Contact USShift to Value-based Payments

As a whole, the healthcare industry is moving towards value-based payments from volume-based or fee-for-service based payments. This system rewards the increment in quality and value of healthcare services. Companies in the pharmaceutical industry are also looking to implement value based purchasing but will face challenges in estimating an appropriate time-frame for manufacturers to demonstrate drug efficacy. Therefore, it will be difficult for new drugs to compete in the value-based payment system.

To gather more insights into our services and their benefits for your business, Request for more info!Get More Info

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice